Compounds 3, 4, and 5 were not fully studied regarding their physicochemical properties, their safety profiles through the in vivo studies, and the consequences of long-term treatment with these biomolecules on FLT3 AML patients. Here, FLT3 is linked to acute myeloid leukemia.